Ken Griffin Novavax Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$10.71 - $17.11 $2.23 Million - $3.57 Million	-208,500 Reduced 14.77%	1,203,100 $15.2 Million
Q2 2024 Aug 14, 2024	BUY	$3.89 - $20.97 $2.5 Million - $13.5 Million	643,300 Added 83.73%	1,411,600 $17.9 Million
Q1 2024 May 15, 2024	BUY	$3.76 - $6.02 $747,488 - $1.2 Million	198,800 Added 34.91%	768,300 $3.67 Million
Q4 2023 Feb 14, 2024	SELL	$4.8 - $7.67 $660,960 - $1.06 Million	-137,700 Reduced 19.47%	569,500 $2.73 Million
Q3 2023 Nov 14, 2023	BUY	$6.81 - $9.74 $1.44 Million - $2.06 Million	211,600 Added 42.7%	707,200 $5.12 Million
Q2 2023 Aug 14, 2023	SELL	$6.67 - $9.52 $1.27 Million - $1.81 Million	-190,200 Reduced 27.73%	495,600 $3.68 Million
Q1 2023 May 15, 2023	SELL	$5.76 - $12.48 $2.35 Million - $5.1 Million	-408,800 Reduced 37.35%	685,800 $4.75 Million
Q4 2022 Feb 14, 2023	BUY	$8.86 - $25.04 $4.86 Million - $13.7 Million	548,700 Added 100.51%	1,094,600 $11.3 Million
Q3 2022 Nov 14, 2022	SELL	$18.2 - $76.12 $16.5 Million - $69.2 Million	-909,000 Reduced 62.48%	545,900 $9.94 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.